Covalent linkage of recombinant hirudin to a novel ionic poly(carbonate) urethane polymer with protein binding sites: determination of surface antithrombin activity
- PMID: 9702317
- DOI: 10.1046/j.1525-1594.1998.05091.x
Covalent linkage of recombinant hirudin to a novel ionic poly(carbonate) urethane polymer with protein binding sites: determination of surface antithrombin activity
Abstract
Surface thrombus formation on implantable biomaterials such as polyurethane is a major concern when utilizing these materials in the clinical setting. Thrombin, which is responsible for thrombus formation and smooth muscle cell activation, has been the target of numerous surface modification strategies in an effort to prevent this phenomenon from occurring. The purpose of this study was to covalently immobilize the potent, specific antithrombin agent recombinant hirudin (rHir) onto a novel polyurethane polymer synthesized with carboxylic acid groups which served as protein attachment sites. The in vitro efficacy of thrombin inhibition by this novel biomaterial surface was then evaluated. Bovine serum albumin (BSA), which was selected as the basecoat protein, was reacted with sulfo-SMCC in a 1:50 molar ratio. This BSA-SMCC complex was then covalently linked to the carboxylated polyurethane (cPU) surface via the crosslinker EDU (cPU-BSA-SMCC). This cPU-BSA-SMCC surface was then reacted with Traut's-modified 125I-rHir, a procedure which created free sulfhydryl groups on rHir (cPU-BSA-SMCC-S-125I-rHir). Using these crosslinking procedures, the cPU-BSA-SMCC-S-125I-rHir segments bound 188 +/- 40 ng/cm2 (n = 60) whereas the controls with non-specifically bound 125I-rHir (Mitrathane + EDC + BSA + 125I-rHir-SH and cPU-BSA + 125I-rHir-SH) bound 13 +/- 8 ng/cm2 and 4 +/- 8 ng/cm2, respectively. Evaluation of these cPU-BSA-SMCC-S-125I-rHir segments for 131I-thrombin inhibition using a chromogenic assay for thrombin showed that a maximum of 2.64 NIHU thrombin was inhibited in contrast to the controls which inhibited bound 0.76 and 0.70 NIHU. Controls with nonspecifically bound 125I-rHir also had 0.31 and 0.76 NIHU 131I-thrombin adherent to their respective surfaces whereas the maximum 131I-thrombin binding to the cPU-BSA-SMCC-S-rHir segments was 1.51 NIHU. Exposure to 131I-thrombin did not result in any release of covalently bound 125I-rHir from the cPU-BSA-SMCC-S-125I-rHir segments. Thus, these results demonstrate that rHir can be covalently bound to this novel polyurethane surface and still maintain potent antithrombin activity.
Similar articles
-
Covalent linkage of recombinant hirudin to poly(ethylene terephthalate) (Dacron): creation of a novel antithrombin surface.Biomaterials. 1997 May;18(10):755-65. doi: 10.1016/s0142-9612(96)00193-7. Biomaterials. 1997. PMID: 9158859
-
Bioengineering of a novel small diameter polyurethane vascular graft with covalently bound recombinant hirudin.ASAIO J. 1998 Sep-Oct;44(5):M653-8. doi: 10.1097/00002480-199809000-00071. ASAIO J. 1998. PMID: 9804516
-
In vivo assessment of a novel dacron surface with covalently bound recombinant hirudin.Cardiovasc Pathol. 1999 May-Jun;8(3):153-9. doi: 10.1016/s1054-8807(99)00005-8. Cardiovasc Pathol. 1999. PMID: 10722238
-
Surface modification with PEG and hirudin for protein resistance and thrombin neutralization in blood contact.Colloids Surf B Biointerfaces. 2010 Dec 1;81(2):389-96. doi: 10.1016/j.colsurfb.2010.07.024. Epub 2010 Jul 15. Colloids Surf B Biointerfaces. 2010. PMID: 20709502 Review.
-
Is the inhibition of both clot-associated thrombin and factor Xa more clinically relevant than either one alone?Blood Coagul Fibrinolysis. 2009 Apr;20(3):207-14. doi: 10.1097/MBC.0b013e3283273529. Blood Coagul Fibrinolysis. 2009. PMID: 19657318 Review.
Cited by
-
Development of small-diameter vascular grafts.World J Surg. 2007 Apr;31(4):682-9. doi: 10.1007/s00268-006-0731-z. World J Surg. 2007. PMID: 17345123 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials